BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE

被引：1
|
作者：
Perry, M. [1 ]
Jang, M. [2 ]
机构：
[1] Royal Alexandra Hosp, Paisley, Renfrew, Scotland
[2] Celltr Healthcare Co Ltd, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3422
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1185
引用
收藏
页码：1879 / 1879
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective
    Alkhatib, Nimer S.
    Almutairi, Abdulaali R.
    Almadi, Majid
    Halloush, Shiraz
    Al-Ruthia, Yazed Sulaiman H.
    Rashdan, Omar
    Al-Shatnawi, Samah
    Azzam, Nahla A.
    Mosli, Mahmoud H.
    Badawoud, Amal M.
    Al Yami, Majed S.
    Alhossan, Abdulaziz
    AlHarbi, Ibtisam
    PLOS ONE, 2024, 19 (11):
  • [2] Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
    Byun, Han Geul
    Jang, Minyoung
    Yoo, Hyun Kyeong
    Potter, James
    Kwon, Taek Sang
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (05) : 735 - 745
  • [3] Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
    Han Geul Byun
    Minyoung Jang
    Hyun Kyeong Yoo
    James Potter
    Taek Sang Kwon
    Applied Health Economics and Health Policy, 2021, 19 : 735 - 745
  • [4] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [5] Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
    Matt Shirley
    Clinical Drug Investigation, 2021, 41 : 1099 - 1107
  • [6] Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
    Shirley, Matt
    CLINICAL DRUG INVESTIGATION, 2021, 41 (12) : 1099 - 1107
  • [7] CT-P13 subcutaneous infliximab in gastroenterology and rheumatology
    Ahmed, Mai
    Bankov, Giulia
    Casey, Dan
    Perry, Martin Edward
    IMMUNOTHERAPY, 2021, 13 (12) : 1001 - 1009
  • [8] 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France
    Kim, J.
    Hong, J. An
    Kudrin, A.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S144 - S145
  • [9] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Hyun Kyeong Yoo
    Han Geul Byun
    Flavio Caprioli
    Mathurin Fumery
    Laurent Peyrin-Biroulet
    Subramanian Sreedhar
    James Potter
    Minyoung Jang
    BMC Health Services Research, 22
  • [10] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Yoo, Hyun Kyeong
    Byun, Han Geul
    Caprioli, Flavio
    Fumery, Mathurin
    Peyrin-Biroulet, Laurent
    Sreedhar, Subramanian
    Potter, James
    Jang, Minyoung
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
12345